Adage Capital Partners Gp, L.L.C. Akero Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 295,000 shares of AKRO stock, worth $13.6 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
295,000
Previous 195,000
51.28%
Holding current value
$13.6 Million
Previous $7.89 Million
99.43%
% of portfolio
0.03%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding AKRO
# of Institutions
296Shares Held
92.2MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$310 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$264 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$257 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$252 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$209 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.14B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...